Long-term follow-up of phase III trial of docetaxel and cisplatin (DP) versus mitomycin, vindesine, and cisplatin (MVP) with concurrent thoracic radiation therapy (TRT) for locally advanced non-small cell lung cancer (OLCSG 0007).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 7048-7048 ◽  
Author(s):  
K. Kiura ◽  
N. Takigawa ◽  
K. Matsuo ◽  
S. Kuyama ◽  
S. Hosokawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Phase Iii Trial ◽  
Thoracic Radiation ◽  
Long Term Follow Up

Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer

2011 ◽  
Vol 51 (4) ◽  
pp. 537-540 ◽  
Author(s):  
Yoshiyuki Tokuda ◽  
Nagio Takigawa ◽  
Toshiyuki Kozuki ◽  
Haruhito Kamei ◽  
Akihiro Bessho ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Phase Ii Trial ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Thoracic Radiation ◽  
Long Term Follow Up

Randomized chemoradiation for patients with locally advanced inoperable non-small cell lung cancer (NSCLC): Long-term follow-up of RTOG 92-04

Lung Cancer ◽  
2000 ◽  
Vol 29 (1) ◽  
pp. 93 ◽  
Author(s):  
R Komaki ◽  
W Seiferheld ◽  
D Ettinger ◽  
J.S Lee ◽  
B Movsas ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Follow Up

O-262 Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study — long-term follow-up data

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S76 ◽  
Author(s):  
Petr Zatloukal ◽  
Lubos Petruzelka ◽  
Milada Zemanova ◽  
Libor Havel ◽  
Ladislav Pecen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Randomized Phase Ii ◽  
Long Term Follow Up ◽  
Sequential Radiochemotherapy

Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer

Lung Cancer ◽  
2005 ◽  
Vol 50 (2) ◽  
pp. 235-245 ◽  
Author(s):  
Dong Wook Kim ◽  
Yu Shyr ◽  
Bashar Shaktour ◽  
Wallace Akerley ◽  
David H. Johnson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Follow Up ◽  
Long Term Survivors

A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors

Lung Cancer ◽  
2002 ◽  
Vol 36 (3) ◽  
pp. 313-319 ◽  
Author(s):  
Tsuyoshi Kodani ◽  
Hiroshi Ueoka ◽  
Katsuyuki Kiura ◽  
Masahiro Tabata ◽  
Nagio Takigawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Randomized Trial ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Long Term Follow Up

Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer: Preliminary report

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 7101-7101 ◽  
Author(s):  
K. Kiura ◽  
Y. Segawa ◽  
M. Tabata ◽  
N. Takigawa ◽  
H. Kamei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Response Rate ◽  
Locally Advanced ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Phase Iii Trial ◽  
Thoracic Radiation

7101 Background: Standard treatment of locally advanced non-small cell lung cancer (NSCLC) is cisplatin-based chemotherapy with concurrent thoracic radiation therapy (TRT). Furuse et al. demonstrated a superiority of mitomycin, vindesine and cisplatin (MVP) chemotherapy with concurrent TRT over that with sequential TRT (JCO 17, 1999). We demonstrated that docetaxel plus cisplatin (DP) chemotherapy with concurrent TRT shows better response rate and survival (Kiura K et al. BJC 89, 2003). We conducted a randomized phase III trial that compared DP with MVP in locally advanced NSCLC patients when concurrently administered with TRT. Methods: We randomly assigned patients with good performance status (PS)-stage IIIA/IIIB NSCLC to receive DP or MVP chemotherapy. Chemotherapy consisted of docetaxel 40 mg/m2 and cisplatin 40 mg/m2 on days 1, 8, 29, & 36 in the DP arm and mitomycin 8 mg/m2 on days 1 & 29, vindesine 3 mg/m2 on days 1, 8, 29, & 36, and cisplatin 80 mg/m2 on days 1 & 29 in the MVP arm. In the both groups, TRT began on day 1 at a dose of 60 Gy (2 Gy per fraction and 5 fractions per week for a total of 30 fractions). Results: Two hundred patients entered the trial between July 2000 and July 2005. Pretreatment characteristics were well balanced between the two treatment arms as follows: male/female 92/7, 88/13; median age (range) 65 (40–75), 64 (34–75); stage IIIA/IIIB 33/66, 33/68; and PS of 0/1 46/53, 50/51, for the DP arm and for the MVP arm, respectively. The response rates for the DP arm and the MVP arm were 78.8% and 70.3%, respectively. The 1- and 2-year survival rates were 81.8% and 59.9% for the DP arm, and were 68.8% and 49.1% for the MVP arm, respectively. Median follow up time is 1.4 years in January 2006. Complete analysis will be fixed in July 2007. Conclusions: The DP arm is exactly reproducing the response rate and survival of the phase II trial we have previously reported. The MVP arm seems to reveal better results than that we expected. Radiation dose and schedule might explain the difference because Furuse et al. splitted 56 Gy of TRT in the MVP arm whereas we did not split 60 Gy of TRT. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document